Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Brashear, H. Roberta; * | Ketter, Nzeeraa; 1 | Bogert, Jenniferb | Di, Jianinga; 2 | Salloway, Stephen P.c | Sperling, Reisad
Affiliations: [a] Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA | [b] Janssen Research & Development, LLC, Raritan, NJ, USA | [c] Brown Medical School, Butler Hospital, Blackstone Blvd., Providence, RI, USA | [d] Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, MA, USA; General Hospital, Harvard Medical School, Boston, MA, USA
Correspondence: [*] Correspondence to: H. Robert Brashear, MD, Janssen Research & Development, 1800 American Boulevard, Pennington, NJ 08534, USA. Tel.: +1 609 730 2501; Fax: +1 609 730 2069; E-mail: rbrashea@janimm.com.
Note: [1] Present address: 141 Leland Avenue, Menlo Park, CA, USA.
Note: [2] Present address: Janssen ChinaR&DCenter, Shanghai, China.
Abstract: Background:Amyloid-related imaging abnormalities with effusion or edema (ARIA-E) reported in patients with mild-to-moderate Alzheimer’s disease in bapineuzumab phase III studies. Objectives:Assess symptoms, clinical severity, and ARIA-E outcomes, and to evaluate effects on cognition and function. Methods:A centralized systematic sequential locked procedure and scoring system for assessment of magnetic resonance imaging scans in 1,331 APOE ɛ4 noncarriers and 1,121 carriers was conducted by experienced and trained pairs of neuroradiologists. Results:Treatment-emergent ARIA-E occurred in 15.8% of bapineuzumab and 0.8% placebo-treated patients. In all treated APOE ɛ4 noncarriers, the percentage of patients with ARIA-E was 5.6%, 13.4%, and 19.9% in the 0.5, 1.0, and 2.0 mg/kg groups respectively, and the incidence of symptomatic ARIA-E was 1.5%, 1.5%, and 7.8%, respectively. In carriers, ARIA-E occurred in 21.2% in the 0.5 mg/kg group, and symptomatic ARIA-E occurred in 2.4%. The clinical severity of ARIA-E in those patients in whom it was detected during the study was mild in 57.1%, 61.3%, and 50.0% of cases in 0.5, 1.0, and 2.0 mg/kg noncarriers respectively, and in 73.8% of cases in 0.5 mg/kg carriers. Vascular risk factors did not appear to increase susceptibility to ARIA-E. Rate of decline in cognition and function measured by changes in ADAS-Cog/11 and DAD total scores did not meaningfully differ in patients with ARIA-E versus those without ARIA-E. Extent of cognitive decline was similar over all visit intervals. Conclusions:Overall, ARIA-E was mild and asymptomatic. ARIA-E did not demonstrate clinically meaningful acute or chronic impact on cognition or function.Registration: NCT00574132 (Bapineuzumab-301), NCT00575055 (Bapineuzumab-302)
Keywords: Amyloid-related imaging abnormality, bapineuzumab, clinical evaluation
DOI: 10.3233/JAD-180675
Journal: Journal of Alzheimer's Disease, vol. 66, no. 4, pp. 1409-1424, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl